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A B S T R A C T
Background: Practically, the initial step of genetic analysis is the extraction of DNA from blood or other cells,
which is often time consuming and cost-intensive. We aimed at establishing a real-time PCR protocol for the
detection of the venous thromboembolism associated mutations factor V Leiden (F5 c.1691G>A; p.R506Q) and
prothrombin (F2) c.20210G>A from whole blood, without DNA extraction.
Methods: F5 c.1691G>A (p.R506Q) and F2 c.20210G>A mutations were determined in 205 EDTA anti-
coagulated whole blood samples from patients who underwent routine clinical genotyping using the DirectBlood
Genotyping PCR Kit (myPOLS Biotec, Konstanz, Germany) together with in-house developed TaqMan primer-
probe assays.
Results: Validity score values of genotype calls using whole blood were similar and did not significantly differ
compared to those using genomic DNA as substrate in PCR. Mutation analysis of 205 whole blood samples
showed a negligible PCR dropout rate (one in 410 reactions) and were in 100% concordance with results ob-
tained by conventional genotyping.
Conclusion: We successfully established a robust and valid real-time PCR protocol for the detection of the venous
thromboembolism associated mutations F5 c.1691G>A (p.R506Q) and F2 c.20210G>A directly from whole
blood.
1. Introduction
Factor V Leiden (F5 c.1691G>A; p.R506Q; rs6025) [1] and the
prothrombin (F2) c.20210G>A (rs1799963) [2] mutation are the
major inherited risk factors of venous thromboembolism manifested as
deep venous thrombosis or pulmonary embolism and have been further
associated with a higher risk of myocardial infarction [3], stroke [4],
and miscarriage [5]. Consequently, routine genetic testing is re-
commended in several clinical circumstances, particularly in patients
with venous thrombosis at younger age, a strong family history of
thrombotic disease, or in women with a history of venous thrombosis
during pregnancy [6].
A variety of methods have been proposed for the detection of
these genetic variants [7,8]. Probably the most commonly used are
real-time polymerase chain reaction (PCR) assays using TaqMan-
probes due to their underlying relatively simple technique and ex-
cellent analytic validity [9–12]. TaqMan technology relies on the 5′-3′
exonuclease activity of the thermostable Taq-DNA polymerase in
combination with allele-specific probes labeled with a distinct
fluorescent reporter dye on the 5′-end and a quencher on the 3′-end
[13]. An allele-specific fluorescence signal is generated by cleavage
and separation of the reporter dye from the quencher when hy-
bridization of the probe to the complementary allelic sequence occurs
during PCR. Incorporation of locked nucleic acids (LNAs) into the
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probe sequence [14] or 3′-end attachment of a minor groove binder
molecule [15] enhances binding affinity to complementary sequences
and allows the generation of relatively short yet highly allele-specific
probes.
However, apart from the fast and accurate TaqMan-probe based
allele-detection technique, the initial step of genetic analysis practically
is the extraction of DNA from blood or other cells, which is often time
consuming and cost-intensive. Direct PCR analysis using blood as sub-
strate, without prior DNA extraction and purification, is generally
hampered by PCR inhibition induced by blood components, especially
hemoglobin and immunoglobulin G [16]. To overcome this problem,
scientists have tried to develop robust DNA polymerases and to identify
PCR additives that may allow PCR amplification in the presence of
blood compounds [16–20]. However, despite these technological real-
time PCR using whole blood directly as a DNA source remained inferior
[16], particularly in terms of efficiency. No real-time PCR protocol for
the detection of the F5 c.1691G>A (p.R506Q) and F2 c.20210G>A
mutations directly from blood has been reported in the current litera-
ture, to date.
In the present study we, therefore, investigated the robustness and
analytic validity of a recently launched Taq-polymerase kit specifically
adapted for real-time PCR directly from blood, the DirectBlood
Genotyping PCR Kit (myPOLS Biotec, Konstanz, Germany), together
with in-house TaqMan primer-probe assays designed for the detection
of the genetic variants F5 c.1691G>A (p.R506Q) and F2
c.20210G>A. We evaluated i) the impact of blood on the performance
of the DirectBlood Genotyping PCR Kit and our assays using whole
blood and extracted genomic DNA as substrates and ii) the reliability of
our direct blood PCR protocol by re-genotyping over 200 blood samples
from patients who previously underwent routine F5 c.1691G>A
(p.R506Q) and F2 c.20210G>A genotyping.
2. Methods
2.1. Patients' samples
In the present study 205 EDTA anti-coagulated whole blood samples
from patients who underwent routine clinical F5 c.1691G>A
(p.R506Q) and F2 c.20210G>A genotyping between 2016 until pre-
sent were used. Additionally, 25 archived genomic DNA samples for
each mutation were recovered to evaluate the performance of our as-
says using different substrates. Blood samples as well as DNA samples
were stored at −20 °C after initial routine genotyping. Samples were
selected based on previously determined genotypes to increase the
number of risk-allele-carriers compared to naturally occurring genotype
frequencies. With respect to the F5 c.1691G>A (p.R506Q) mutation,
the present study included 104 carriers homozygous for the common
allele, 100 carriers of the heterozygous genotype, and one carrier
homozygous for the rare allele. With respect to the F2 20210G>A
genetic variant, the study included 174 carriers homozygous for the
common allele, 30 carriers of the heterozygous genotype, and one
carrier homozygous for the rare allele. All patients gave written con-
firmed consent for clinical F5 c.1691G>A (p.R506Q) and F2
c.20210G>A testing.
2.2. Routine genotyping
For routine genotyping, genomic DNA was extracted from 200 μL
EDTA blood using the peqGOLD® Blood DNA Mini kit (VWR, Vienna,
Austria) and eluated in 200 μL elution buffer corresponding to a DNA
concentration of up to 75 ng/μL according to the information of the
manufacturer. Genotyping of the F5 c.1691G>A (p.R506Q) and F2
c.20210G>A variants was carried out by commercially available
TaqMan® genotyping assays (assay ID: C__11975250_10 and
C___8726802_20, respectively; Thermo Fisher Scientific, Waltham, MA,
USA) used with TaqMan® Genotyping PCR Master Mix (Thermo Fisher
Scientific) on a LightCycler® 480 Real-Time PCR System (F. Hoffmann-
La Roche Ltd., Basle, Switzerland).
2.3. Direct blood TaqMan-PCR
2.3.1. Primers and probes
TaqMan probe based genotyping assays were designed to detect the
F5 c.1691G>A (p.R506Q) and F2 20210G>A mutations. Each gen-
otyping assay includes a pair of PCR primers flanking the respective
genetic variation and two allele-specific TaqMan probes containing
LNAs and distinct fluorescent reporter dyes to detect the specific mu-
tation. TaqMan probes labeled with the 5′ fluorescent reporter dye 6-
carboxy-fluorescein (6FAM) are specific for the respective common
alleles and TaqMan probes labeled with hexachloro-fluorescein (HEX)
are specific for the respective rare alleles. Adhering to recommended
fluorescent reporter dyes and non-fluorescent quencher combinations, a
non-fluorescent Black Hole Quencher™ 1 (BHQ1) is attached to the 3′
end of each TaqMan probe [14]. Primer and probe sequences are given
in Table 1. All oligonucleotides were synthesized by Microsynth Inc.
(Balgach, Switzerland).
2.3.2. Sample preparation
Blood samples were thawed at room temperature and homogenized
by vortexing. Blood samples were diluted to 2% in nuclease-free water
by adding of 10 μL blood to 490 μL water. Diluted blood samples were
heated for 10min at 80 °C to inactivate potentially present blood-borne
pathogens. After the heating step, blood samples were placed on ice and
immediately used as substrates in PCR.
2.3.3. TaqMan PCR
The DirectBlood Genotyping PCR Kit (myPOLS) was delivered as a
freeze-dried lyocake together with a respective rehydration buffer.
According to the instructions of the manufacturer, the lyocake was
rehydrated by adding 218 μL of the rehydration buffer, resulting in
250 μL of a ready-to-use 2× PCR master mix. Synthesized primer and
probes were used to produce 4× genotyping assays with concentrations
of 3600 nM of each PCR primer and 800 nM of each TaqMan probe.
PCR was performed in a 20 μL volume containing 10 μL of 2×
DirectBlood Genotyping PCR master mix, 5 μL of the in-house manu-
factured 4× primer-probe assays, and 5 μL of 2% diluted blood.
Alternatively, 5 μL of previously extracted, undiluted genomic DNA was
used to compare the performance of the DirectBlood Genotyping PCR
Kit using different substrates. All TaqMan PCRs were carried out on a
LightCycler® 480 Real-Time PCR System (Roche Diagnostics, Vienna,
Austria) under the following thermocycling conditions: 95 °C for 10min
followed by 45 cycles of 95 °C for 15 s and 60 °C for 1min. Non-tem-
plate controls as well as samples homozygous for the respective rare
allele were included in each run as duplicates.
Table 1
Primer and probe sequences for F5 c.1691G>A (p.R506Q) and F2
20210G>A detection.
F5 c.1691G>A (p.R506Q)
F5 forward 5′ GAA AGG TTA CTT CAA GGA CAA AAT ACC
F5 reverse 5′ AGA CAT CGC CTC TGG GCT AAT AG
G1681 (R506)-probe 6FAM - ACA GGc gAg GAA T - BHQ1
A1681 (Q506)-probe HEX - ACA GGc aag GAA T - BHQ1
F2 c.20210G>A
F2 forward 5′ GCT CCT GGA ACC AAT CCC GTG
F2 reverse 5′ CCA GAG AGC TGC CCA TGA ATA G
G20210-probe 6FAM - CTC AGc gAg CCT C - BHQ1
A20210- probe HEX - CTC AGc aag CCT C - BHQ1
Locked nucleotides (LNA) are denoted in lower case; the nucleotide com-
plementary to the target mutation is underlined. 6FAM, 6-carboxy-fluorescein;
HEX, hexachloro-fluorescein; BHQ1, Black Hole Quencher 1™.
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Genotypes were determined by LightCycler® software 1.5.
Genotyping analysis software groups similar samples and automatically
calls genotypes. Additionally, the software assigns a score between 0
and 1 to each call, indicating the validity of the call (0= invalid;
1= highly valid). Samples failed to be automatically called were
manually assigned to the most probably genotype by visual inspection
or determined as uncertain or negative.
2.4. Statistics
The Kolmogorov-Smirnov test was used as a test for normality of
score values obtained by LightCycler® software 1.5 indicating that score
values were not normally distributed. Differences in score values using
either whole blood or genomic DNA as substrates were tested for sta-
tistical significance with the non-parametric Wilcoxon test. P-va-
lues< .05 were considered significant. Statistical analyses were per-
formed with SPSS 25.0 for Windows (IBM, Armonk, New York, USA).
3. Results
The impact of whole blood on the performance of the DirectBlood
Genotyping PCR Kit (myPOLS) together with in-house TaqMan primer-
probe assays was evaluated by using whole blood samples and corre-
sponding genomic DNA samples of the same patients as substrates.
Scatter plots obtained by real-time PCR of the F5 c.1691G>A
(p.R506Q) and F2 c.20210G>A mutations using either whole blood or
genomic DNA are displayed in Fig. 1. Overall, PCRs using undiluted
genomic DNA samples as substrates showed stronger fluorescence sig-
nals compared to whole blood samples most probably reflecting dif-
ferent amounts of input DNA. However, all genotypes from direct blood
PCR could be called automatically and were in 100% concordance with
those using genomic DNA as substrate in PCR. Furthermore, validity
score values of automatically called genotypes using whole blood were
highly similar and did not differ significantly compared to those using
genomic DNA [F5 c.1691G>A (p.R506Q): Median score value= 0.97
Fig. 1. Scatter plots obtained by real-time PCR of F5 c.1691G>A (p.R506Q) (A, C) and F2 c.20210G>A (B, D) mutations using either genomic DNA (A, B) or whole
blood (C,D) as substrates. Allele X= common allele, allele Y= rare allele. Allele X homozygotes are clustered in blue; allele Y homozygotes are clustered in green;
heterozygotes are clustered in red. Non-template controls (NTCs) are clustered in black. NTCs as well as samples homozygous of the respective rare allele were
included in each run as duplicates. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
K. Geiger et al. Clinica Chimica Acta 488 (2019) 221–225
223
(range=0.90–1) and 0.98 (range=0.90–1) for whole blood and for
genomic DNA, respectively (p= .551); F2 c.20210G>A: Median score
value=0.94 (range=0.85–1) and 0.94 (range=0.88–1) for whole
blood and for genomic DNA, respectively (p= .367)].
To evaluate the reliability of our direct blood PCR protocol, we
compared the results previously obtained from conventional routine
genotyping of the F5 c.1691G>A (p.R506Q) and F2 c.20210G>A
variants with results now obtained from direct blood PCR totally in-
cluding 205 subjects. Raw data including fluorescence signal strength
and score values of each individual analysis are given in Supplementary
Table S.1. For the F5 c.1691G>A (p.R506Q) mutation, genotypes of
203 samples were automatically called correctly (median score= 0.96;
range= 0.68–1), one sample was automatically called as uncertain and
one sample as negative. The genotype of the uncertain samples could be
assigned correctly by manual editing after visual inspection
(Supplementary Fig. S.1). The analysis of the negative sample was re-
peated showing the correct automatically called genotype
(score= 0.94) in the repeated analysis pointing to handling errors in
the initial analysis. With respect to the F2 c.20210G>A variant, gen-
otypes of all 205 samples were automatically called correctly (median
score= 0.97; range= 0.65–1).
4. Discussion
In the present study, we successfully developed a robust and valid
real-time PCR protocol for the detection of the venous thromboembo-
lism associated mutations F5 c.1691G>A (p.R506Q) and F2
c.20210G>A directly from blood: Mutation analysis of 205 whole
blood samples showed a negligible PCR dropout rate (one in 410 initial
reactions) and a 100% concordance with results previously obtained by
conventional genotyping. The reported method is reliable, cost-effec-
tive, and accelerates time to result supporting rapid clarification of a
potential underlying genetic background of venous thromboembolism.
Our protocol is based on the use of the commercially available
DirectBlood Genotyping PCR Kit (myPOLS) together with in-house de-
veloped TaqMan-assays for real-time mutation detection. Of note, also
other suppliers have released robust DNA polymerases resistant to in-
hibitors present in whole blood [21] such as the Phusion® Blood II DNA
Polymerase (Thermo Fisher Scientific), the Hemo KlenTaq Polymerase
(New England Biolabs, Ipswich, MA), the KAPA Blood DNA Polymerase
(Kapa Biosystems, Wilmington, MA), or the KOD FX DNA Polymerase
(Toyobo, Osaka, Japan). However, these polymerases show either
proofreading 3′-5′ exonuclease activity or lack 5′-3′ exonuclease ac-
tivity and, therefore, are not applicable for TaqMan-based real-time
PCR. The DNA polymerase included in the DirectBlood Genotyping PCR
Kit with its 5′-3′ exonuclease activity and its robustness makes the kit
particularly suitable for TaqMan-based real-time PCR directly from
whole blood samples.
The DirectBlood Genotyping PCR Kit is available as a freeze-dried
lyophilisate and, therefore, can be shipped at ambient temperature
without the need for cool packaging. The lyophilisate and its rehydra-
tion buffer may contain substances to preserve polymerase functionality
during the freeze-drying process as well as to increase PCR inhibitor
resistance. In this regard, the disaccharide trehalose is known to be
both, a stabilizer of enzyme activity in dry conditions [22] and a potent
PCR enhancer [23] and might, therefore, be a component of the Di-
rectBlood Genotyping PCR Kit. Notably, trehalose or other PCR en-
hancers significantly lower DNA melting temperature [23] and conse-
quently may affect probe specificity. Therefore, performance and
specificity of primer-probe assays established under regular PCR con-
ditions may have to be re-evaluated using the DirectBlood Genotyping
PCR Kit. Particularly, the use of relatively short and highly allele-spe-
cific probes is required which in our study was achieved by in-
corporation of LNAs into TaqMan probe sequences [14]. Alternatively,
attachment of a minor groove binding molecule at the 3′-end of the
probes may probably show similarly marked effects [15,24]. However,
minor groove binder probes are proprietary to Thermo Fisher Scientific
whereas the main patent of LNAs expired in 2017 making LNA oligo-
nucleotides ubiquitously available.
Blood components such as hemoglobin and hematin are known to
significantly quench fluorescence signaling [16] limiting final blood
concentration and consequently DNA input in TaqMan-probe based
real-time PCR. In this regard, as stated in the manufacturers' instruc-
tions of the DirectBlood Genotyping PCR Kit the final concentration of
whole blood should be 0.5%. According to the normal concentration of
white blood cells varying between 4000 and 10,000 per microliter in
whole blood of healthy adults [25], 5 μL of 2% diluted whole blood as
used in PCR corresponds to 800–2000 genome equivalents or
2.9–7.4 ng genomic DNA, which appears sufficient for germline muta-
tion detection by real-time PCR. However, sensitivity of TaqMan-based
detection of blood-borne pathogens or somatic mutations from diluted
blood samples may be limited especially in cases of low levels and low
allelic burden, respectively. Moreover, a very low white blood cell
count, which can be caused by certain autoimmune disorders, cancer,
viral infections or medication intake [26–28], may also affect sensi-
tivity of germline mutation detection by real-time PCR directly from
diluted blood samples. That said, in our study we did not correct for
white blood cell count and received valid results from all included
patients.
In summary, we present a reliable protocol for the detection of F5
c.1691G>A (p.R506Q) and F2 c.20210G>A mutations directly from
whole blood saving costs and time. The described method is easily re-
producible in every laboratory with real-time PCR technology and may
therefore stimulate further research and assist the clinician in the di-
agnosis of inherited venous thrombosis.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.cca.2018.11.016.
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